Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults

Ensitrelvir is a novel selective inhibitor of the 3C-like protease of SARS-CoV-2, which is essential for viral replication. This phase 1 study of ensitrelvir assessed its safety, tolerability, and pharmacokinetics of single (part 1, n = 50) and multiple (part 2, n = 33) ascending oral doses. Effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Ryosuke, Sonoyama, Takuhiro, Fukuhara, Takahiro, Kuwata, Aya, Matsuo, Yumiko, Kubota, Ryuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578392/
https://www.ncbi.nlm.nih.gov/pubmed/36094202
http://dx.doi.org/10.1128/aac.00632-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578392/
https://www.ncbi.nlm.nih.gov/pubmed/36094202
http://dx.doi.org/10.1128/aac.00632-22

Ejemplares similares